RCI BMT, which conducts prospective research within the CIBMTR, provides researchers in the field of hematopoietic cell transplantation (HCT) with infrastructure and expertise in HCT clinical trial conduct and analysis. RCI BMT’s goal is to generate data allowing novel and innovative ideas to move into the larger Phase II or Phase III in settings such as the National Institute of Health’s BMT CTN or the national cooperative groups.
Clinical trials services available through RCI BMT include assistance with funding proposals; protocol development and approvals; management of study conduct; data auditing, management, and analysis; and financial administration. Principal investigators may also contract for specific services as needed, such as support with surveys, site selection and management, sample management, and more. The RCI BMT team can work with Principal Investigators to seek funding from a variety of sources including government agencies, foundations, pharmaceutical companies, and private corporations.
Investigators interested in utilizing the RCI BMT mechanism for multicenter studies may submit study proposals at any time.
